Chicago has always been a hotbed for technological innovation and now the Windy City is getting involved with the medical field through a rising start-up known as Tempus. Tempus was co-founded by Eric Lefkofsky in 2015 with the goal of helping to revolutionize the way that customers and medical health professionals interact with and access important medical data. The company is now valued at north of $1 billion and this has allowed Tempus to earn the coveted Unicorn Status.
The goal of Tempus is to utilize data in a way that helps to streamline and maximize the effectiveness of cancer care in the modern medical world. Having seen how the system works up close, through a personal relationship, Lefkofsky came to the realization that there is a ton of room for improvement within the field. So, Tempus compiles data from multiple sources before porting it into an accessible database. This database is then utilized by patients, family members and healthcare professionals in order to track cancer care approaches and see which ones are most effective.
We are currently living in the data-driven age of technology and Lefkofsky’s approach as the co-founder of Tempus is serving as a unique opportunity to help change lives through data. Leaning on clinical data and molecular data, Tempus is quickly becoming vital in the search for trends among cancer care patients. Tempus relies not only on old data but it also ports data from patients that are currently undergoing treatment. The data collection system is advanced enough that it can utilize digital database and simple enough that it can be used to port in handwritten doctor notes into a searchable platform.
Right now, Tempus employs nearly 400 workers and their business forecast shows that the company will be adding nearly 30 new employees every single month from here on out. With success in their approach, Tempus has quickly captured the eye of several major investors. It was recently announced that Tempus had earned an additional $80 million in investments which pushes their 3-year-total to just north of $210 million. With this kind of early success, the sky appears to be the limit for Tempus.